Create Free Account

By creating account you will get access to hot stocks & personalised emails

Star Combo Pharma Ltd

Consumer Defensive AU S66

0.11AUD
-(-%)

Last update at 2024-11-11T23:00:00Z

Day Range

0.110.11
LowHigh

52 Week Range

0.100.17
LowHigh

Fundamentals

  • Previous Close 0.11
  • Market Cap17.56M
  • Volume0
  • P/E Ratio-
  • Dividend Yield2.85%
  • EBITDA1.73M
  • Revenue TTM26.02M
  • Revenue Per Share TTM0.19
  • Gross Profit TTM 4.82M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -3.45491M -1.08163M -7.46331M -0.90641M -2.33797M
Minority interest - - - - -
Net income -4.00296M -0.69635M -7.87582M -0.34869M -1.72677M
Selling general administrative 3.26M 3.90M 4.39M 4.72M 4.51M
Selling and marketing expenses 0.53M 0.64M 0.70M 1.01M 1.87M
Gross profit 7.16M 5.61M 4.61M 5.29M 3.68M
Reconciled depreciation 0.74M 0.78M 0.32M 0.31M 0.21M
Ebit 1.14M 0.55M -0.88982M -0.51254M -2.31136M
Ebitda 1.88M 1.33M -0.20177M 0.35M -1.93383M
Depreciation and amortization 0.74M 0.78M 0.69M 0.86M 0.38M
Non operating income net other - - - - -
Operating income 1.14M 0.55M -0.88982M -0.51254M -2.31136M
Other operating expenses 23.87M 23.82M 29.32M 41.24M 24.21M
Interest expense 0.19M 0.17M 0.24M 0.39M 0.03M
Tax provision 0.55M -0.38528M 0.41M -0.55773M -0.61120M
Interest income 0.23M 0.05M 0.29M 0.41M 0.11M
Net interest income -0.05847M -0.11925M -0.12964M -0.39387M 0.06M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.55M -0.38528M 0.41M -0.55773M -0.61120M
Total revenue 24.70M 22.88M 26.72M 38.84M 21.41M
Total operating expenses 6.33M 6.55M 7.20M 7.69M 6.48M
Cost of revenue 17.54M 17.27M 22.12M 33.55M 17.73M
Total other income expense net -4.35822M -1.63086M -6.57349M -0.39387M -0.02662M
Discontinued operations - - - - -
Net income from continuing ops -4.00296M -0.69635M -7.87582M -0.34869M -1.72677M
Net income applicable to common shares -4.00296M -0.69635M -7.87582M -0.34869M -1.72677M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 42.82M 42.23M 43.44M 43.32M 54.72M
Intangible assets - 0.69M 0.70M 2.51M 2.89M
Earning assets - - - - -
Other current assets 0.17M 0.12M 0.14M 0.16M 0.66M
Total liab 9.30M 8.97M 8.04M 7.13M 10.22M
Total stockholder equity 33.32M 33.09M 35.41M 36.19M 44.50M
Deferred long term liab - - - - -
Other current liab 1.90M 1.73M 1.50M 1.25M 0.93M
Common stock 67.29M 67.29M 67.22M 67.32M 67.74M
Capital stock - 67.29M 67.22M 67.32M 67.74M
Retained earnings -35.57463M -10.30640M -7.05570M -6.51192M 1.23M
Other liab - 0.61M 0.08M 0.46M 0.60M
Good will - 0.00000M 0.00000M 0.00000M 6.34M
Other assets - 0.71M 0.92M 0.90M 1.46M
Cash 2.16M 9.49M 10.39M 17.32M 26.60M
Cash and equivalents - 6.50M 6.00M 12.07M 20.00M
Total current liabilities 4.87M 4.33M 4.01M 3.55M 4.66M
Current deferred revenue - - - - 1.04M
Net debt 1.86M -5.29558M -6.27118M -14.02697M -20.98697M
Short term debt 0.16M 0.16M 0.17M 0.17M 0.67M
Short long term debt - 0.04M 0.04M 0.03M 0.48M
Short long term debt total 4.03M 4.19M 4.12M 3.30M 5.61M
Other stockholder equity - -23.89213M -24.75478M -24.61774M -24.47893M
Property plant equipment - 22.72M 22.74M 13.48M 8.69M
Total current assets 18.35M 18.10M 19.08M 26.43M 35.34M
Long term investments - - - - -
Net tangible assets - 32.40M 34.71M 33.68M 35.27M
Short term investments 5.20M - - - -
Net receivables 4.48M 4.30M 3.18M 4.40M 2.53M
Long term debt - 0.00917M 0.08M 0.12M 1.49M
Inventory 6.34M 4.20M 5.37M 4.50M 5.38M
Accounts payable 2.82M 2.44M 2.34M 2.12M 2.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.61M -23.89213M -24.75478M -24.61774M -24.47893M
Additional paid in capital - - - - -
Common stock total equity - - - - 67.74M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.68M - - - -
Deferred long term asset charges - - - - -
Non current assets total 24.46M 24.12M 24.36M 16.90M 19.38M
Capital lease obligations - 4.15M 4.01M 3.15M 3.54M
Long term debt total - 4.03M 3.95M 3.12M 4.95M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -3.22858M 4.05M -7.52551M -3.62706M -3.92281M
Change to liabilities 1.02M 0.02M 0.71M -0.62065M -0.51459M
Total cashflows from investing activities -3.22858M -3.24440M -7.52551M -3.62706M -3.92281M
Net borrowings 0.07M -0.16908M -2.08445M 1.64M -0.08781M
Total cash from financing activities -0.05344M -0.16908M -2.08445M 26.63M 1.79M
Change to operating activities 0.07M 0.05M 0.19M 0.18M -0.20730M
Net income -4.00296M -0.69635M -7.87582M -0.34869M -1.72677M
Change in cash -1.40527M -2.87958M -9.27844M 21.98M -4.32077M
Begin period cash flow 4.39M 7.27M 26.60M 4.62M 8.94M
End period cash flow 2.99M 4.39M 17.32M 26.60M 4.62M
Total cash from operating activities 1.88M 0.09M 0.33M -1.01816M -2.18515M
Issuance of capital stock 0.08M - - 33.32M 1.89M
Depreciation 0.70M 0.78M 0.69M 0.86M 0.38M
Other cashflows from investing activities -0.50000M 4.05M -0.26813M -0.25000M -0.25000M
Dividends paid - - - -2.06241M -
Change to inventory 1.17M -0.86956M 0.88M -0.44151M -0.34280M
Change to account receivables -1.15083M -0.28542M -0.28996M 0.25M 0.59M
Sale purchase of stock 0.08M - - -8.33795M -0.01000M
Other cashflows from financing activities -0.06189M -0.13635M -0.16106M 3.75M 0.05M
Change to netincome 4.06M 1.45M 5.76M -0.90021M -0.36414M
Capital expenditures 2.73M 7.29M 7.26M 2.78M 4.24M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.13M 0.54M 0.47M 0.25M 0.09M
Stock based compensation - - - - -
Other non cash items - -0.08711M 7.56M 0.04M 1.52M
Free cash flow -2.72858M -7.20770M -7.25738M -2.78215M -4.23861M

Peer Comparison

Sector: Consumer Defensive Industry: Household & Personal Products

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
S66
Star Combo Pharma Ltd		 - -% 0.11 - - 0.67 0.53 0.49 6.14
MCP
Mcpherson'S Ltd		 0.02 5.26% 0.40 - 16.08 0.39 0.63 0.35 16.32
PTL
Prestal Holdings Limited		 0.007 8.64% 0.09 - - 0.67 0.50 0.52 5.04
ZNO
Zoono Group Ltd		 -0.002 7.41% 0.03 - - 8.81 1.48 8.51 -1.3808
AN1
Anagenics Ltd		 - -% 0.008 - - 0.34 1.36 0.26 -3.9793

Reports Covered

Stock Research & News

View All

Profile

Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. It operates in two segments, OEM Division and Austoyou Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its products under the Costar, Living Healthy, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is headquartered in Smithfield, Australia.

Star Combo Pharma Ltd

171-177 Woodpark Road, Smithfield, NSW, Australia, 2164

Key Executives

Name Title Year Born
Ms. Su Zhang M.B.A. CEO & Exec. Director NA
Mr. JinXing Zhang B.S. Founder, MD & Director NA
Mr. James Ni Chief Financial Officer NA
Mr. He Ben B.S. Chief Operating Officer NA
Mr. Patrick James Raper F.A.C.I.D., FAICD, FCPA Company Sec. NA
Ms. Su Zhang M.B.A. CEO & Executive Director NA
Ms. Su Zhang M.B.A. CEO & Executive Director NA
Mr. Patrick James Raper F.A.C.I.D., FAICD, FCPA Company Secretary NA
Ms. Su Zhang M.B.A. CEO & Executive Director NA
Mr. Patrick James Raper F.A.C.I.D., FAICD, FCPA Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.